Denali Therapeutics Inc. Common Stock (DNLI)

Price$20.54

Favorite Metrics

Price vs S&P 500 (26W)25.09%

Price vs S&P 500 (4W)-7.51%

Market Capitalization$3.26B

All Metrics

Book Value / Share (Quarterly)$6.49

P/TBV (Annual)2.44x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.70

Price vs S&P 500 (YTD)20.45%

Net Profit Margin (TTM)-36.53%

EPS (TTM)$-2.97

10-Day Avg Trading Volume1.34M

EPS Excl Extra (TTM)$-2.97

EPS (Annual)$-2.97

ROI (Annual)-50.28%

Net Profit Margin (5Y Avg)-332.00%

Cash / Share (Quarterly)$5.56

ROA (Last FY)-44.77%

EBITD / Share (TTM)$-3.13

ROE (5Y Avg)-32.10%

Operating Margin (TTM)-49.71%

Cash Flow / Share (Annual)$-2.70

P/B Ratio3.21x

P/B Ratio (Quarterly)2.54x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)8.97x

Net Interest Coverage (TTM)-167.00x

ROA (TTM)-44.20%

EV / EBITDA (TTM)89.67x

EPS Incl Extra (Annual)$-2.97

Current Ratio (Annual)9.16x

Quick Ratio (Quarterly)8.82x

3-Month Avg Trading Volume1.72M

52-Week Price Return63.90%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$8.10

P/S Ratio (Annual)9.86x

Asset Turnover (Annual)0.29x

52-Week High$23.77

Operating Margin (5Y Avg)-352.15%

EPS Excl Extra (Annual)$-2.97

CapEx CAGR (5Y)25.11%

Tangible BV CAGR (5Y)17.48%

26-Week Price Return33.83%

Quick Ratio (Annual)8.85x

13-Week Price Return12.59%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)9.16x

Enterprise Value$3,057.758

Asset Turnover (TTM)0.25x

Book Value / Share Growth (5Y)-7.43%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-43.93%

Cash / Share (Annual)$5.56

3-Month Return Std Dev66.44%

Net Income / Employee (TTM)$-1

ROE (Last FY)-50.56%

EPS Basic Excl Extra (Annual)$-2.97

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-2.97

Receivables Turnover (Annual)152.00x

ROI (TTM)-49.86%

P/S Ratio (TTM)9.56x

Pretax Margin (5Y Avg)-332.49%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.67

Price vs S&P 500 (52W)28.81%

Year-to-Date Return24.59%

5-Day Price Return5.92%

EPS Normalized (Annual)$-2.97

ROA (5Y Avg)-26.23%

Net Profit Margin (Annual)-43.94%

Month-to-Date Return7.14%

Cash Flow / Share (TTM)$-0.77

EBITD / Share (Annual)$-3.13

Operating Margin (Annual)-59.51%

ROI (5Y Avg)-31.99%

EPS Basic Excl Extra (TTM)$-2.97

P/TBV (Quarterly)2.27x

P/B Ratio (Annual)2.54x

Pretax Margin (TTM)-36.53%

Book Value / Share (Annual)$6.49

Price vs S&P 500 (13W)9.72%

Beta1.07x

P/FCF (Annual)7.89x

Revenue / Share (TTM)$0.00

ROE (TTM)-50.13%

52-Week Low$12.31

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.42

4.36

Industry Peers — Biological Products(89)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
DNLIDenali Therapeutics Inc. Common Stock	9.56x	—	—	—	$20.54
AMGNAmgen Inc	5.20x	9.95%	73.30%	2.93%	$350.16
GILDGilead Sciences Inc	5.71x	2.40%	78.83%	133.64%	$135.87
ARGXargenx SE American Depositary Shares	12.59x	89.56%	150.91%	—	$834.45
BNTXBioNTech SE American Depositary Share	9.06x	-11.81%	84.21%	—	$105.19
BIIBBiogen Inc. Common Stock	2.72x	2.22%	75.69%	-18.77%	$183.34
MRNAModerna, Inc. Common Stock	10.91x	-39.93%	70.32%	—	$54.59
NBIXNeurocrine Biosciences Inc	4.64x	21.45%	98.18%	2.31%	$131.59
EXELExelixis Inc	4.89x	6.85%	96.39%	31.10%	$43.61
TECHBio-Techne Corp.	7.72x	1.64%	66.60%	-20.58%	$60.58
IBRXImmunityBio, Inc. Common Stock	74.42x	668.31%	99.34%	—	$8.20

About

Denali Therapeutics is a biotechnology company developing therapeutics for neurodegenerative diseases, with a lead program targeting LRRK2 inhibition for Parkinson's disease. Its pipeline includes multiple candidates leveraging proprietary delivery technologies, including antibody and enzyme transport vehicles designed to penetrate the blood-brain barrier.